No Detail Found!

Evaluation of Quality of Warfarin Therapy by Assessing Patient's Time in Therapeutic Range at a Tertiary Care Hospital in Pakistan.

Author(s)
Haris Hakem Section of Neurology, Department of Internal Medicine, Aga Khan University Hospital, Karachi, Pakistan
Ammar Zaman Khan General Surgery, Benazir Bhutto Hospital, Rawalpindi, Pakistan
Kashif Aziz Resident Internal Medicine, Aga Khan University Hospital, Karachi, Pakistan
Ayesha Abbasi Aga Khan University Hospital, Karachi, Pakistan
Anam Haider Resident Internal Medicine, Aga Khan University Hospital, Karachi, Pakistan
Bushra Moiz Hematology, Aga Khan University Hospital Karachi, Pakistan
Mohammad Wasay Section of Neurology, Department of Internal Medicine, Aga Khan University Hospital, Karachi, Pakistan
Abstract
Objective: To assess the time in therapeutic range in patients on warfarin anti-coagulation therapy. Methods: The retrospective chart review was conducted at Aga Khan University Hospital, Karachi, and comprised data of patients having undergone anti-coagulation with warfarin from January 2013 to April 2015. To determine the mean time in therapeutic range, Rosendaal method was used. Association of time in therapeutic range with the composite outcome, bleeding and thromboembolic events was also assessed. Percentage of patients with time in therapeutic range <60% was calculated. Results: There were 92 patients whose median time in therapeutic range was 34.9% (interquartile range: 20.0-55.7). Overall, 71(77.2%) patients had time in therapeutic range below 60% which had statistically significant correlation with the composite outcome (p<0.05). Number of comorbids was significant in predicting time in therapeutic range and patients with time in therapeutic range< 60% (p<0.05). Conclusion: Subjects had poor anti-coagulation quality. It might be prudent to move towards novel oral anticoagulant drugsas the first choice for therapeutic anti-coagulation.
Publication Details
Page(s) 1339-1344
DOI DOI not available
Published Journal: Journal of Pakistan Medical Association, Volume: 68, Issue: 9, Year: 2018

Request the full text from PASTIC

References
AgenoW,GallusAS,WittkowskyA,CrowtherM,HylekEM,PalaretiG, 2012.American College of Chest Physicians evidence-based clinical practice guidelines,Chest 141 e44S -e88S
ConnollySJ,PogueJ,EikelboomJ,FlakerG,CommerfordP,FranzosiMG, .Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range, 35 146 -
WallentinL,YusufS,EzekowitzMD,AlingsM,FlatherM,FranzosiMG, .Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial,Lancet. 2010 Sep 376 975 -83
SingerDE,HellkampAS,PicciniJP,MahaffeyKW,LokhnyginaY,PanG, .Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial,2013 Feb 19 e000067 -e000067
BastakotiS,KhanalS,DahalB,PunNT, 2013.Adherence and nonadherence to treatments: focus on pharmacy practice in Nepal,J Clin Diagn Res 7 754 -7
AhmedW,AsifR,KhanUM, 2007.Compliance, frequency of target INR achievement and complications in patients on long term oral anticoagulant therapy,Pak J Cardiol 18 7 -11
FarooqF,MujtabaSF, 2012.Frequency of achieving target INR in patients with prosthetic heart valves,Pakistan Heart J 45 121 -5
RosendaalFR,CannegieterSC,van der MeerFJ,BriëtE., 1993.A method to determine the optimal intensity of oral anticoagulant therapy,Thromb Haemost 69 236 -9
RoseAJ,MillerDR,OzonoffA,BerlowitzDR,AshAS,ZhaoS, 2013.Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence,CHEST 143 751 -7
BangOY,HongKS,HeoJH,KooJ,KwonSU,YuKH, 2014.New oral anticoagulants may be particularly useful for Asian stroke patients,J Stroke 16 73 -80
ErikssonN,WadeliusM., 2012.Prediction of warfarin dose: why, when and how?,Pharmacogenomics 13 429 -40
DlottJS,GeorgeRA,HuangX,OdehM,KaufmanHW,AnsellJ, 2014.A national assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation,Circulation 129 1407 -14
MillerCS,GrandiSM,ShimonyA,FilionKB,Eisenberg MJ, 2012.Metaanalysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation,Am J Cardiol 110 453 -60
KhanM,WasayM, 2016.New Oral Anticoagulants: Need and Challenges in a Developing Country,J Coll Physicians Surg Pak 26 551 -2
Wigle P, Hein B, Bloomfield HE, Tubb M, Doherty M. Updated guidelines on outpatient anticoagulation. Am Fam Physician. 2013 Apr 15;87(8):556-66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23668445.
Rose AJ, Berlowitz DR, Frayne SM, Hylek EM. Measuring quality of oral anticoagulation care: Extending quality measurement to a new field. Jt Comm J Qual Patient Saf. 2009 Mar;35(3):146-55
0

Citations

0

Downloads

96

Views